Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 9, 2025
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
GlobeNewswire
·
April 9, 2025
SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today announced that it has submitted a clinical trial protocol …
Biomarkers Market Worth $93.8 billion | MarketsandMarkets™.
GlobeNewswire
·
April 9, 2025
Delray Beach, FL, April 09, 2025 (GLOBE NEWSWIRE) -- Biomarkers Market , valued at US$54.8 billion in 2023, is forecasted to grow at a robust CAGR of 10.2%, reaching US$57.7 billion in 2024 and an impressive US$93.8 billion by 2029 according to a published …
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
GlobeNewswire
·
April 9, 2025
Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc …
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire
·
April 9, 2025
Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs) or …
Arialief Supplement: Vitamins Reviews and Complaints for Neuropathic Pain
GlobeNewswire
·
April 9, 2025
HONOLULU, April 09, 2025 (GLOBE NEWSWIRE) -- Arialief is a premium dietary supplement specifically designed to target the root causes of neuropathic discomfort. Whether your symptoms include burning, tingling, numbness, or stabbing nerve pain, Arialief …
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
GlobeNewswire
·
April 9, 2025
CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide Non-Dilutive Funding Expands Pipeline and …
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
GlobeNewswire
·
April 9, 2025
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being …
PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors
GlobeNewswire
·
April 9, 2025
Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent director to join the Board since 2024 Longtime board member and former Chairman Dr. Gian Fulgoni will retire DELRAY …
M6P Therapeutics to Host Virtual KOL Event to Discuss the Lysosomal Storage Disorders Treatment Landscape on April 22, 2025
GlobeNewswire
·
April 9, 2025
ST. LOUIS, Mo., April 09, 2025 (GLOBE NEWSWIRE) -- M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation enzyme replacement and gene therapies for lysosomal storage disorders (LSDs), today announced …
World Leaders in Proteomics and Proteoform Biology to Convene at the 3rd International Top-Down Proteomics Symposium
GlobeNewswire
·
April 9, 2025
The Symposium will feature scientific leaders who are creating cutting edge technologies and approaches for building the bridge from genotype to phenotype. This is ushering in the era of proteoform-specific biology …
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
GlobeNewswire
·
April 9, 2025
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) ( …
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
GlobeNewswire
·
April 9, 2025
FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy Total Revenue $19 million, representing +17% growth year over year FDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA …
Theratechnologies présente ses résultats financiers pour le premier trimestre de 2025 et passe en revue ses principales réalisations
GlobeNewswire
·
April 9, 2025
La FDA approuve EGRIFTA WRMC (la formulation F8 de la tésamoréline) pour traiter l’excès de graisse viscérale abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie Les revenus totaux s’élèvent à 19 millions de dollars, en hausse de 17 % …
Beta Bionics to Host Investor Event on June 22, 2025
GlobeNewswire
·
April 9, 2025
IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, …
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
GlobeNewswire
·
April 9, 2025
DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company’s previously announced Ratio Change on its American Depositary Shares (“ …
Mars Veterinary Health Underscores Long-Term Commitment to Research & Innovation in Groundbreaking Science Impact Report
GlobeNewswire
·
April 9, 2025
BIRMINGHAM, England, April 09, 2025 (GLOBE NEWSWIRE) -- Today, Mars Veterinary Health published its inaugural Science Impact Report: Pets, Purpose …
Preliminary results for the year ended 31 December 2024
GlobeNewswire
·
April 9, 2025
~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1 Operating EBITDA2 loss of £(15.3) …
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
GlobeNewswire
·
April 9, 2025
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
GlobeNewswire
·
April 9, 2025
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation Establishes framework for Makana’s kidney, heart and islet cell programs to …
Dentsply Sirona to Host First Quarter Conference Call on May 8th
GlobeNewswire
·
April 9, 2025
CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am …